• Center for Chronic Lymphocytic Leukemia

    Dana-Farber/Brigham and Women's Cancer Care

    The Center for Chronic Lymphocytic Leukemia (CLL) is part of the Hematologic Oncology (Blood Cancers) Treatment Center at Dana-Farber/Brigham and Women's Cancer Center. Our program promotes a comprehensive approach to the treatment of patients with CLL and provides a centralized hub for CLL research.

    About the Program

    The Center for Chronic Lymphocytic Leukemia (CLL) provides care for patients with chronic lymphocytic leukemia (CLL), and offers access to clinical trials of exciting new drugs, as well as extensive prognostic testing, tissue banking and stem cell transplantation for CLL.

    Patients may access a comprehensive range of services specialized for CLL treatment, including:

    From the time of diagnosis, Dana-Farber offers a personalized CLL risk-assessment, which provides detailed, patient-specific information about an individual's disease and prognosis. Our CLL-focused physicians then work with patients to use this information in planning and implementing treatment strategies. We offer patients with CLL specialized clinical trials, which give patients the opportunity to receive novel therapies on clinical trials. Our ultimate research goal is to improve current therapies to benefit all patients.

     

    The Treatment Team

    The Center for Chronic Lymphocytic Leukemia (CLL) treatment team includes physicians and clinicians with extensive experience caring for patients with CLL.

    Chronic Lymphocytic Leukemia Physicians

    Jennifer R. Brown, MD, PhD, Director
    Matthew Davids, MD 

    Chronic Lymphocytic Leukemia Nursing and Physician Assistant Team

    Jeffrey Hellman, PA-C
    Karen Francoeur, BSN, RN

    Our Lymphoma Program physicians treat patients with all types of lymphoma. We work closely with our transplant service team when CLL patients require bone marrow/stem cell transplantation.

     

    Clinical Research

    Patients have the opportunity to participate in trials for new therapies for all phases of Chronic Lymphocytic Leukemia (CLL), including advanced CLL. These trials include:

    • Agents that prime CLL cells to die when they are hit with chemotherapy
    • Drugs that block key drivers of CLL cell growth, including kinase inhibitors

    Learn more about clinical trials for CLL patients.

    Translational science, which quickly moves laboratory findings into clinical practice, is also a key focus of the Center for Chronic Lymphocytic Leukemia. This includes:

    • Providing CLL samples to a large network of collaborators who are working to better understand how CLL develops and how we can best target it with the goal of finding a cure
    • Examining genetic material of a variety of CLLs in order to identify genetic changes that cause CLL

    Genetic Study of Familial Chronic Lymphocytic Lymphoma

    Dana-Farber is currently enrolling participants for a Genetic Study of Familial Chronic Lymphocytic Lymphoma. This study, led by Jennifer R. Brown, MD, PhD, seeks to identify the genes that cause the disease, in order to develop methods of prevention and diagnosis counseling. To be eligible, participants must have at least two first-degree relatives (e.g., parent, sibling, or child) who have a lymphoma or lymphoproliferative disorder. For more information, including detailed eligibility guidelines and participation requirements, contact lead investigator Jennifer R Brown, MD, PhD or study coordinator Alexander Vartanov.

    Learn more about the Harvard Study of Genetic Factors that Lead to Lymphoma 

     

    Contact Us

    New Patients

    Chronic Lymphocytic Leukemia patients may call 617-632-3245 or 617-632-5138, or use this online form to make an appointment.

    Current Patients

    Contact your doctor directly, or for general inquiries, call the Hematologic Malignancies program at 617-632-6140.

    Fax

    617-632-3730 

    Mailing address

    Hematologic Malignancies Division
    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Boston, MA 02215

     
     
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms